Blueprint Medicines Corporation (BPMC)
US — Healthcare Sector
Automate Your Wheel Strategy on BPMC
With Tiblio's Option Bot, you can configure your own wheel strategy including BPMC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BPMC
- Rev/Share 8.8384
- Book/Share 5.3794
- PB 24.0472
- Debt/Equity 0.3588
- CurrentRatio 2.8017
- ROIC -0.1759
- MktCap 8365206696.0
- FreeCF/Share -2.3728
- PFCF -55.4321
- PE -52.8305
- Debt/Assets 0.1027
- DivYield 0
- ROE -0.4889
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BPMC | Wedbush | Outperform | Neutral | -- | $129 | June 2, 2025 |
| Resumed | BPMC | Morgan Stanley | -- | Equal Weight | -- | $100 | March 20, 2025 |
| Initiation | BPMC | Wolfe Research | -- | Outperform | -- | -- | March 18, 2025 |
| Initiation | BPMC | Jefferies | -- | Buy | -- | $135 | March 17, 2025 |
| Initiation | BPMC | Scotiabank | -- | Sector Outperform | -- | $150 | March 7, 2025 |
News
About Blueprint Medicines Corporation (BPMC)
- IPO Date 2015-04-30
- Website https://www.blueprintmedicines.com
- Industry Biotechnology
- CEO Kathryn Haviland
- Employees 682
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.